Cargando…
Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma
BACKGROUND: Ovarian serous cystadenocarcinoma (OSC) is the most prevalent histological subtype of ovarian cancer (OV) and presents a serious threat to women's health. Anoikis is an essential component of metastasis, and tumor cells can get beyond it to become viable. The impact of anoikis on OS...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404752/ https://www.ncbi.nlm.nih.gov/pubmed/37554782 http://dx.doi.org/10.1016/j.heliyon.2023.e18708 |
_version_ | 1785085368168611840 |
---|---|
author | Zhu, Yu-Ting Wu, Shuang-Yue Yang, Song Ying, Jie Tian, Lu Xu, Hong-Liang Zhang, He-Ping Yao, Hui Zhang, Wei-Yu Jin, Qin-Qin Yang, Yin-Ting Jiang, Xi-Ya Zhang, Nan Yao, Shun Zhou, Shu-Guang Chen, Guo |
author_facet | Zhu, Yu-Ting Wu, Shuang-Yue Yang, Song Ying, Jie Tian, Lu Xu, Hong-Liang Zhang, He-Ping Yao, Hui Zhang, Wei-Yu Jin, Qin-Qin Yang, Yin-Ting Jiang, Xi-Ya Zhang, Nan Yao, Shun Zhou, Shu-Guang Chen, Guo |
author_sort | Zhu, Yu-Ting |
collection | PubMed |
description | BACKGROUND: Ovarian serous cystadenocarcinoma (OSC) is the most prevalent histological subtype of ovarian cancer (OV) and presents a serious threat to women's health. Anoikis is an essential component of metastasis, and tumor cells can get beyond it to become viable. The impact of anoikis on OSC, however, has only been the topic of a few studies. METHODS: The mRNA sequencing and clinical information of OSC came from The Cancer Genome Atlas Target Genotype-Tissue Expression (TCGA TARGET GTEx) dataset. Anoikis-related genes (ARGs) were collected by Harmonizome and GeneCards websites. Centered on these ARGs, we used unsupervised consensus clustering to explore potential tumor typing and filtered hub ARGs to create a model of predictive signature for OSC patients. Furthermore, we presented clinical specialists with a novel nomogram based on ARGs, revealing the underlying clinical relevance of this signature. Finally, we explored the immune microenvironment among various risk groups. RESULTS: We identified 24 ARGs associated with the prognosis of OSC and classified OSC patients into three subtypes, and the subtype with the best prognosis was more enriched in immune-related pathways. Seven ARGs (ARHGEF7, NOTCH4, CASP2, SKP2, PAK4, LCK, CCDC80) were chosen to establish a risk model and a nomogram that can provide practical clinical decision support. Risk scores were found to be an independent and significant prognostic factor in OSC patients. The CIBERSORTx result revealed an inflammatory microenvironment is different for risk groups, and the proportion of immune infiltrates of Macrophages M1 is negatively correlated with risk score (r(s) = −0.21, P < 0.05). Ultimately, quantitative reverse transcription polymerase chain reaction (RT-PCR) was utilized to validate the expression of the seven pivotal ARGs. CONCLUSION: In this study, based on seven ARGs, a risk model and nomogram established can be used for risk stratification and prediction of survival outcomes in patients with OSC, providing a reliable reference for individualized therapy of OSC patients. |
format | Online Article Text |
id | pubmed-10404752 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-104047522023-08-08 Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma Zhu, Yu-Ting Wu, Shuang-Yue Yang, Song Ying, Jie Tian, Lu Xu, Hong-Liang Zhang, He-Ping Yao, Hui Zhang, Wei-Yu Jin, Qin-Qin Yang, Yin-Ting Jiang, Xi-Ya Zhang, Nan Yao, Shun Zhou, Shu-Guang Chen, Guo Heliyon Research Article BACKGROUND: Ovarian serous cystadenocarcinoma (OSC) is the most prevalent histological subtype of ovarian cancer (OV) and presents a serious threat to women's health. Anoikis is an essential component of metastasis, and tumor cells can get beyond it to become viable. The impact of anoikis on OSC, however, has only been the topic of a few studies. METHODS: The mRNA sequencing and clinical information of OSC came from The Cancer Genome Atlas Target Genotype-Tissue Expression (TCGA TARGET GTEx) dataset. Anoikis-related genes (ARGs) were collected by Harmonizome and GeneCards websites. Centered on these ARGs, we used unsupervised consensus clustering to explore potential tumor typing and filtered hub ARGs to create a model of predictive signature for OSC patients. Furthermore, we presented clinical specialists with a novel nomogram based on ARGs, revealing the underlying clinical relevance of this signature. Finally, we explored the immune microenvironment among various risk groups. RESULTS: We identified 24 ARGs associated with the prognosis of OSC and classified OSC patients into three subtypes, and the subtype with the best prognosis was more enriched in immune-related pathways. Seven ARGs (ARHGEF7, NOTCH4, CASP2, SKP2, PAK4, LCK, CCDC80) were chosen to establish a risk model and a nomogram that can provide practical clinical decision support. Risk scores were found to be an independent and significant prognostic factor in OSC patients. The CIBERSORTx result revealed an inflammatory microenvironment is different for risk groups, and the proportion of immune infiltrates of Macrophages M1 is negatively correlated with risk score (r(s) = −0.21, P < 0.05). Ultimately, quantitative reverse transcription polymerase chain reaction (RT-PCR) was utilized to validate the expression of the seven pivotal ARGs. CONCLUSION: In this study, based on seven ARGs, a risk model and nomogram established can be used for risk stratification and prediction of survival outcomes in patients with OSC, providing a reliable reference for individualized therapy of OSC patients. Elsevier 2023-07-26 /pmc/articles/PMC10404752/ /pubmed/37554782 http://dx.doi.org/10.1016/j.heliyon.2023.e18708 Text en © 2023 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Zhu, Yu-Ting Wu, Shuang-Yue Yang, Song Ying, Jie Tian, Lu Xu, Hong-Liang Zhang, He-Ping Yao, Hui Zhang, Wei-Yu Jin, Qin-Qin Yang, Yin-Ting Jiang, Xi-Ya Zhang, Nan Yao, Shun Zhou, Shu-Guang Chen, Guo Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma |
title | Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma |
title_full | Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma |
title_fullStr | Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma |
title_full_unstemmed | Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma |
title_short | Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma |
title_sort | identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404752/ https://www.ncbi.nlm.nih.gov/pubmed/37554782 http://dx.doi.org/10.1016/j.heliyon.2023.e18708 |
work_keys_str_mv | AT zhuyuting identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma AT wushuangyue identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma AT yangsong identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma AT yingjie identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma AT tianlu identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma AT xuhongliang identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma AT zhangheping identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma AT yaohui identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma AT zhangweiyu identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma AT jinqinqin identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma AT yangyinting identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma AT jiangxiya identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma AT zhangnan identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma AT yaoshun identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma AT zhoushuguang identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma AT chenguo identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma |